AbbVie announced today that Robert A. Michael has taken on the role of Chief Executive Officer (CEO) and joined the company’s Board of Directors, effective immediately. As previously announced, Mr. Michael succeeds Richard A. Gonzalez, who has been the CEO since AbbVie’s inception in 2013. Mr. Gonzalez will now serve as Executive Chairman of the Board of Directors.
Mr. Michael previously served as President and Chief Operating Officer of AbbVie and has been a longstanding member of AbbVie’s Executive Leadership Team. In his prior roles, he was responsible for global commercial operations, finance, corporate human resources, global operations, business development, and corporate strategy for the company. He was appointed Vice Chairman and President in 2022, Vice Chairman of Finance and Commercial Operations in 2021, and Chief Financial Officer in 2018. With over 31 years of experience, Mr. Michael has held leadership roles across multiple businesses, including pharmaceuticals, aesthetics, diagnostics, diabetes care, and nutrition. He began his career with Abbott as part of the financial development program.
“It is an honor to step into the CEO role at AbbVie and build on Rick’s achievements,” said Robert A. Michael, CEO of AbbVie. “Our mission to deliver innovative medicines to patients has never been more critical, and the opportunities before us are exciting. I look forward to working with our approximately 50,000 employees to drive the next phase of AbbVie’s growth. I am committed to preserving our strong culture and delivering a remarkable impact for our patients, employees, shareholders, and communities. I would like to thank Rick for his strong leadership over the past 11 years, and I am grateful he will continue to contribute to AbbVie as Executive Chairman.”
“The board and I have great confidence in Rob, and we know that his combination of experience, skills, and vision uniquely prepares him to lead AbbVie,” said Richard A. Gonzalez, Executive Chairman of AbbVie. “We have the right leadership team in place, along with the strategy and financial foundation to ensure a bright future for AbbVie. It has been a privilege to serve as CEO, and I look forward to working alongside Rob and the AbbVie Board of Directors to continue delivering on our promise to patients around the world.
AbbVie’s mission is to discover and deliver innovative medicines and solutions that address serious health issues today and tackle the medical challenges of tomorrow. We strive to have a significant impact on people’s lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and through products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.
AbbVie Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “expect,” “anticipate,” “project,” and similar expressions, as well as the use of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological, and other factors that may affect AbbVie’s operations is detailed in Item 1A, “Risk Factors,” of AbbVie’s 2023 Annual Report on Form 10-K, filed with the Securities and Exchange Commission, and updated by subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation, and specifically declines, to publicly release any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
